Suzanne L. Topalian
#87,677
Most Influential Person Now
American oncologist
Suzanne L. Topalian's AcademicInfluence.com Rankings
Suzanne L. Topalianmedical Degrees
Medical
#1286
World Rank
#1610
Historical Rank
Oncology
#87
World Rank
#91
Historical Rank
Download Badge
Medical
Why Is Suzanne L. Topalian Influential?
(Suggest an Edit or Addition)According to Wikipedia, Suzanne Louise Topalian is an American surgical oncologist. She is the Bloomberg-Kimmel Professor of Cancer Immunotherapy in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine. In this role, she studies human anti-tumor immunity.
Suzanne L. Topalian's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. (2012) (6726)
- Immune checkpoint blockade: a common denominator approach to cancer therapy. (2015) (3000)
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2002) (2901)
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (2003) (2799)
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. (2010) (2647)
- Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006) (2575)
- Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. (1988) (2109)
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. (2014) (2043)
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy (2014) (1984)
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012) (1936)
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (1998) (1897)
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (2016) (1848)
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. (2005) (1640)
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (2003) (1591)
- Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. (1998) (1339)
- Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. (1990) (1226)
- Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer (2018) (1203)
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. (2012) (1192)
- Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. (1994) (1121)
- Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. (1994) (1118)
- Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 (2011) (1103)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) (1015)
- Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. (1994) (983)
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (2016) (976)
- Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. (2005) (969)
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010) (888)
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) (806)
- Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. (2003) (784)
- Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. (2006) (778)
- The role of CD4+ T cell responses in antitumor immunity. (1998) (711)
- Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007) (679)
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. (2013) (665)
- Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. (1993) (615)
- Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. (2002) (564)
- Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. (1989) (547)
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody (2012) (502)
- Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma (2005) (500)
- Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study (2005) (495)
- Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. (1988) (435)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020) (399)
- Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma (2001) (379)
- A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma (2002) (368)
- Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. (1987) (358)
- Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. (2005) (338)
- Alterations of immune response of non-small cell lung cancer with Azacytidine (2013) (335)
- Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. (1998) (334)
- Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. (1989) (323)
- Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. (1999) (319)
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019) (316)
- PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival (2013) (309)
- Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. (1994) (297)
- Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes (1996) (290)
- Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. (1999) (284)
- Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma (2006) (262)
- Antagonists of PD-1 and PD-L1 in Cancer Treatment. (2015) (254)
- Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. (2018) (251)
- Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (241)
- Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines (2000) (241)
- A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. (1998) (224)
- Cancer immunotherapy comes of age. (2011) (221)
- Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. (1993) (218)
- Mechanisms regulating PD-L1 expression on tumor and immune cells (2019) (216)
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade (2015) (212)
- Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR. (2004) (199)
- Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. (1991) (194)
- Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. (1999) (194)
- Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial (2019) (188)
- Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade (2014) (186)
- Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. (1995) (183)
- Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma (2017) (181)
- Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells (1999) (179)
- Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. (1992) (166)
- In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. (1994) (162)
- Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. (1994) (162)
- Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. (1995) (160)
- Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. (1997) (159)
- Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. (1991) (138)
- Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice (2000) (136)
- Identification and Functional Characterization of Neo-Poly(A) Polymerase, an RNA Processing Enzyme Overexpressed in Human Tumors (2001) (135)
- Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. (2003) (131)
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. (2014) (125)
- Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens (2003) (118)
- Clinical trial designs for the early clinical development of therapeutic cancer vaccines. (2001) (115)
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. (2020) (115)
- Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. (2003) (114)
- Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. (1989) (113)
- Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) (2017) (111)
- The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma (2016) (110)
- Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab (2018) (110)
- MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. (1994) (110)
- Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. (2020) (105)
- Opportunities and challenges in the development of experimental drug combinations for cancer. (2011) (103)
- Targeting Immune Checkpoints in Cancer Therapy. (2017) (102)
- Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy (2009) (100)
- Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. (1998) (100)
- Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. (2015) (100)
- Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. (2003) (99)
- Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. (2010) (94)
- Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. (1992) (94)
- Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells (1994) (92)
- An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers. (2017) (91)
- Structural basis for the recognition of mutant self by a tumor-specific, MHC class II–restricted T cell receptor (2007) (89)
- Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. (2014) (89)
- Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial (2016) (86)
- Immunotherapy: The Path to Win the War on Cancer? (2015) (83)
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020) (83)
- Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction (1991) (82)
- Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. (1994) (81)
- CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation (2004) (80)
- The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. (1992) (77)
- Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade (2021) (76)
- Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting (2015) (75)
- Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. (2004) (73)
- The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma (1995) (73)
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). (2013) (73)
- Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. (1989) (72)
- Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer (2020) (71)
- Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. (1996) (70)
- Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. (2020) (69)
- The Development of Gene Therapy for the Treatment of Cancer (1993) (68)
- Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. (1992) (68)
- Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. (1990) (67)
- Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma (2003) (67)
- Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy (2017) (63)
- Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade (2019) (63)
- T-cell recognition of human melanoma antigens. (1993) (61)
- Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. (2002) (60)
- Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. (1993) (59)
- Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. (1994) (59)
- Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. (1993) (59)
- A phase I trial of intravenous interleukin-6 in patients with advanced cancer. (1994) (59)
- A Prospective Randomized Trial Evaluating Colloid Versus Crystalloid Resuscitation in the Treatment of the Vascular Leak Syndrome Associated with Interleukin‐2 Therapy (1994) (57)
- Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial (2021) (57)
- Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy (2017) (57)
- Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358 (2019) (57)
- Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen (2004) (57)
- Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. (1992) (51)
- Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies (2008) (51)
- Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. (1993) (50)
- Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
- Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. (1992) (50)
- Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma (2006) (47)
- PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation (2014) (46)
- PD-L 1 Expression in the Merkel Cell Carcinoma Microenvironment : Association with In fl ammation , Merkel Cell Polyomavirus , and Overall Survival (2013) (44)
- Structural insights into the editing of germ-line–encoded interactions between T-cell receptor and MHC class II by Vα CDR3 (2012) (43)
- Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans. (1990) (40)
- Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells. (2010) (40)
- LBA46An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck (SCCHN) (2017) (37)
- Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358. (2018) (36)
- Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers. (2017) (36)
- Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. (1993) (36)
- A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. (1992) (36)
- Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy. (2017) (34)
- Integrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in Melanoma (2020) (34)
- Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines (2006) (34)
- Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma (2021) (33)
- Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. (1992) (32)
- First Tissue-Agnostic Drug Approval Issued. (2017) (32)
- Meeting report: The future of preclinical mouse models in melanoma treatment is now (2013) (31)
- Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma. (2017) (30)
- Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks. (1990) (30)
- Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: Analysis by cytokine secretion (2005) (30)
- Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy (2018) (29)
- Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. (2009) (27)
- PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. (2012) (26)
- Nonsynonymous somatic mitochondrial mutations occur in the majority of cutaneous melanomas (2008) (25)
- Balance and imbalance in the immune system: life on the edge. (2014) (25)
- Cellular immunotherapy of cancer (1990) (25)
- Necrotizing enterocolitis: a review of animal models. (1984) (24)
- Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patients. (2002) (24)
- Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (23)
- Recognition of Shared Melanoma Antigens by Human Tumor-Infiltrating Lymphocytes (1992) (23)
- Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. (1987) (22)
- Structure-Based Design of Altered MHC Class II–Restricted Peptide Ligands with Heterogeneous Immunogenicity (2013) (22)
- N‐linked carbohydrates in tyrosinase are required for its recognition by human MHC class II‐restricted CD4+ T cells (2001) (21)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). (2012) (21)
- An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). (2017) (20)
- Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells. (1999) (20)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2023) (20)
- Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor. (1990) (20)
- 22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (2015) (19)
- Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes. (1995) (19)
- Microenvironment and Immunology Evidence for a Role of the PD-1 : PD-L 1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma (2013) (19)
- Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas (2020) (18)
- TNF/TIL Human Gene Therapy Clinical Protocol: Original Protocol, April 23, 1990 (1990) (16)
- A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. (2013) (16)
- Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. (2016) (15)
- Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011 (2012) (14)
- Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry. (1992) (14)
- NSCLC, early stageNeoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer (2016) (14)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Melanoma and other skin tumors (2012) (13)
- Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest (1994) (12)
- A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors. (2014) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Tumor‐specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines (2002) (9)
- Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors (2016) (8)
- 520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358 (2022) (7)
- Abstract 662: The differential association of PD-1, PD-L1, and CD8+ cells with response to pembrolizumab and presence of Merkel cell polyomavirus (MCPyV) in patients with Merkel cell carcinoma (MCC) (2017) (6)
- Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- 365 days: Nature's 10 (2014) (6)
- Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- Enterocolitis in Patients After Antibody Blockade of CTLA-4. (2005) (5)
- Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop (2020) (5)
- Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients. (1993) (5)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (5)
- 1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL. (2014) (5)
- Abstract 446: Differential expression of immuno-regulatory genes associated with PD-L1 display: Implications for clinical blockade of the PD-1/PD-L1 pathway in melanoma. (2013) (4)
- Translating Research into Therapies (2012) (4)
- Tumor-specific lysis by long-term cultured tumor-infiltrating lymphocytes (1987) (4)
- Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition. (2020) (3)
- Abstract CT079: Neoadjuvant PD-1 blockade in resectable lung cancer (2018) (3)
- Selection of optimal therapy for neuroblastoma: A Study of the Immunomodulatory Effects of Surgery and Irradiation in the Murine C1300 Neuroblastoma Model (1987) (3)
- PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers. (2012) (3)
- Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade. (2020) (3)
- The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas (2020) (3)
- Abstract 4619: Epigenetic therapy and sensitization of lung cancer to immunotherapy. (2013) (2)
- Growth and antitumor activity of tumor-involved draining lymph node cells versus tumor-infiltrating lymphocytes from patients with renal cell cancer (1987) (2)
- 820P Nivolumab (NIVO) +/- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naïve or -refractory basal cell carcinoma (BCC) (2022) (2)
- Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma (2003) (2)
- Tumour immunology: Editorial overview (2001) (2)
- Abstract 4750: The immunosuppressive tumor microenvironment (TME) in nasopharyngeal carcinoma: implications for immunotherapy (2018) (2)
- NMDA Receptor-PSD-95 Protein Interactions Treatment of Ischemic Brain Damage by Perturbing (2006) (2)
- Selection of Optimal Therapy for Neuroblastoma: A Study of the Immunomodulatory Effects of Surgery and Irradiation in the Murine C1300 Neur oblastoma Model (1987) (2)
- Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule (2016) (1)
- Co-stimulatory signals upregulate PD-1 expression on human T lymphocytes: Implications for cancer immunotherapy (2006) (1)
- Relationship of Blood Transfusion and Clinical Outcomes in Patients With Acute Coronary SyndromesRao SV, Jollis JG, Harrington RA, et al (Duke Univ, Durham, NC; Univ of Alberta, Edmonton, Canada; Univ of Kentucky, Lexington; et al) JAMA 292:1555–1562, 2004§ (2006) (1)
- Early Revascularization and Long-term Survival in Cardiogenic Shock Complicating Acute Myocardial InfarctionHochman JS, for the SHOCK Investigators (New York Univ; et al) JAMA 295:2511–2515, 2006§ (2007) (1)
- Q&A: Suzanne Topalian on immune therapies. (2013) (1)
- 711 Interim results of a phase 2 study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition (2022) (1)
- Tumor-specific lysis by tumor-infiltrating lymphocytes derived from melanomas (1988) (1)
- Abstract 4693: Characterization of the tumor immune microenvironment in head and neck squamous cell carcinoma (SCCHN) (2018) (1)
- Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies (2012) (1)
- Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor G4 (2012) (1)
- Abstract 6584: The ‘AstroPath' platform for spatially resolved, single cell analysis of the tumor microenvironment (TME) using multispectral immunofluorescence (mIF) (2020) (1)
- PATHOLOGY INFORMATICS SUMMIT 2018 (2018) (1)
- Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. (2022) (1)
- Tumor‐associated MHC II‐restricted phosphopeptides: New targets for immune recognition (2008) (1)
- Abstract 1464: The tumor immune microenvironment is similar in anal squamous cell carcinomas (SCCs) from HIV-infected and uninfected patients (2016) (1)
- Clinical T rial D esigns f or t he E arly C linical D evelopment of T herapeutic C ancer V accines (2001) (0)
- Abstract CT096: Clinical activity, immune and viral correlates of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (2016) (0)
- necrosis factor-alpha in response to autologous tumor stimulation secrete granulocyte-macrophage colony-stimulating factor and tumor Tumor-infiltrating lymphocytes derived from select B-cell lymphomas (2011) (0)
- Science Journals — AAAS (2020) (0)
- Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting (2015) (0)
- LB1029 Correlation of merkel virus-specific CD8 T cells with response to immunotherapy in merkel cell carcinoma (2022) (0)
- 299 Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive merkel cell carcinoma (2021) (0)
- Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. (2023) (0)
- New approaches to the immunotherapy of cancer (1988) (0)
- Abstract IA19: Response and resistance PD-1 pathway blockade (2015) (0)
- Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer (2023) (0)
- a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the (1999) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) (0)
- T Cells + MHC-Restricted CD8 Cancer-Associated Antigen by Nonclassical Recognition of a Shared Human Prostate (1999) (0)
- Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma (2002) (0)
- Randomized S tudy o f H igh-Dose a nd L ow-Dose I nterleukin-2 in P atients W ith M etastatic R enal C ancer (2003) (0)
- Abstract IA01: Immunologic heterogeneity of cancer: Determinants of response and resistance to immunotherapy (2015) (0)
- MHC class I antigen restriction of tumor recognition by lymphocytes infiltrating human melanomas (1990) (0)
- Abstract IA7: Blockade of immunologic checkpoints in cancer therapy: The B7-H1/PD-1 pathway (2011) (0)
- Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma (2023) (0)
- 231 A novel discovery pipeline identifies melanoma-specific antibodies in patients responding to immune checkpoint inhibitors (2020) (0)
- Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011 (2012) (0)
- Crystal structure of a gp100:44-59 peptide-HLA-DR4 complex enables design of an altered peptide ligand with enhanced immunogenicity (100.25) (2010) (0)
- 50 Merkel cell polyomavirus-specific CD8 T cells in blood, but not in tumors, correlate with immunotherapy response in merkel cell carcinoma (2022) (0)
- 266 PD-1 blockade and T cell responses in merkel cell carcinoma (2017) (0)
- 288 The COX-2 pathway as a mediator of resistance to anti-PD-1 therapy (2021) (0)
- K 3 Tumor ‐ intrinsic beta ‐ catenin signaling mediates tumor ‐ immune avoidance (2016) (0)
- IN VITRO PREDICTORS OF CLINICAL RESPONSE IN MELANOMA PATIENTS RECEIVING TUMOR INFILTRATING LYMPHOCYTE (TIL) IMMUNOTHERAPY (1993) (0)
- Safety and immunologic correlates of allogeneic melanoma GVAX (MelGVAX), a genetically engineered whole-cell melanoma vaccine. (2014) (0)
- Abstract LB-154: Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small cell lung carcinoma (NSCLC): A proposal for quantitative immune-related pathologic response criteria (irPRC) (2018) (0)
- Abstract IA21: Translating immunotherapy from melanoma to other skin cancers (2020) (0)
- Abstract 1312: Transcriptional signatures associated with lack of response to anti-PD-1 therapy in patients with renal cell carcinoma (2015) (0)
- Melanoma and immunotherapy bridge 2015 K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR in melanoma (2016) (0)
- 241 Characterization of the tumor immune microenvironment in anal squamous cell carcinomas from HIV(+) versus HIV(-) patients (2016) (0)
This paper list is powered by the following services:
Other Resources About Suzanne L. Topalian
What Schools Are Affiliated With Suzanne L. Topalian?
Suzanne L. Topalian is affiliated with the following schools:
